CureVac Shareholders Face Pivotal Takeover Vote

The fate of German biotech firm CureVac hangs in the balance as shareholders prepare for a landmark decision that could transfer control to industry giant BioNTech. With a critical vote scheduled for late November, investors are weighing whether the proposed acquisition represents their best outcome or if the competitive landscape has already been decided.

On November 25, 2025, CureVac’s extraordinary general meeting will see shareholders decide on the complete acquisition by BioNTech. The proposed terms offer approximately $5.46 per CureVac share, protected against BioNTech stock fluctuations through a specialized collar mechanism. This arrangement provides price stability regardless of market movements in BioNTech’s valuation leading up to the transaction’s completion.

The Read more...